ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.

ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.

ANI announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2029 in a private offering to persons reasonably ...